NewEdge Advisors’s SAB Biotherapeutics SABS Stock Holding History

NewEdge Advisors’s Portfolio SABS Stock Details SABS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-14	Closed	-$64	–	3978
2024 Q1	$64	Sell	14 -1	-7%	-$6	﹤0.01%	3718
2023 Q4	$100	Hold	15	–	–	﹤0.01%	3640
2023 Q3	$91	Hold	15	–	–	﹤0.01%	3369
2023 Q2	$120	Hold	15	–	–	﹤0.01%	3414
2023 Q1	$64	Hold	15	–	–	﹤0.01%	3351
2022 Q4	$0	Buy	+15	New	+$137	﹤0.01%	4183

Other funds holding SABS

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Sessa Capital New York $5.51B AUM 47.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Pathstone Holdings Englewood, New Jersey $25.1B AUM 22.95% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

FPB

First PREMIER Bank Sioux Falls, South Dakota $619M AUM 20.21% 1-Year Est. Return

NewEdge Advisors's SABS Position: Q2 2024 in Review

NewEdge Advisors sold out of SAB Biotherapeutics (SABS) in Q2 2024, closing a stake of 14 shares — an estimated $64 sold.

NewEdge Advisors first reported a position in SABS in Q4 2022 and held it in 6 quarters. The position peaked at $120 in Q2 2023. 22 funds tracked by Wall St. Rank hold SABS as of Q2 2024.

NewEdge Advisors reported no remaining SAB Biotherapeutics position as of Q2 2024 after selling out during the quarter.
NewEdge Advisors sold 14 SAB Biotherapeutics shares in Q2 2024, an estimated $64.
NewEdge Advisors first reported a position in SAB Biotherapeutics in Q4 2022 and held it in 6 quarters.
NewEdge Advisors's SAB Biotherapeutics position peaked at $120 in Q2 2023.
22 funds tracked by Wall St. Rank held SAB Biotherapeutics as of Q2 2024.

Based on NewEdge Advisors's 13F filing for Q2 2024, filed 16 Aug 2024.